When will CorMedix report its financial results?

CorMedix Inc. will report its financial results for the third quarter of 2024 before the market opens on October 30, 2024.

What is the name of CorMedix's lead product and when was it approved by the FDA?

The lead product of CorMedix is DefenCath, which was approved by the FDA on November 15, 2023.

Where can investors find more information about CorMedix?

To learn more about CorMedix, one can visit their official website at www.cormedix.com.

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

Q: What time is the corporate update conference call scheduled for?

CorMedix will host a corporate update conference call at 8:30 AM Eastern Time on October 30, 2024.

10/23/24 8:30:00 AM ET

$CRMD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRMD alert in real time by email

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

*Wednesday, October 30*^th @ 8:30am EDT
Domestic:	1-844-481-2557
International:	1-412-317-0561
Webcast:	Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors

[email protected]

(617) 430-7576

Get the next $CRMD alert in real time by email

Date	Price Target	Rating	Analyst
6/30/2025		Buy → Hold	D. Boral Capital
6/30/2025	$20.00	Buy	H.C. Wainwright
3/7/2025	$18.00	Outperform	Leerink Partners
1/13/2025	$15.00	Buy	D. Boral Capital
8/26/2024	$13.00	Buy	Rodman & Renshaw
8/10/2023	$6.00	Outperform	RBC Capital Mkts

Date

Price Target

Rating

Analyst

6/30/2025

Buy → Hold

D. Boral Capital

6/30/2025

$20.00

Buy

H.C. Wainwright

3/7/2025

$18.00

Outperform

Leerink Partners

1/13/2025

$15.00

Buy

D. Boral Capital

8/26/2024

$13.00

Buy

Rodman & Renshaw

8/10/2023

$6.00

Outperform

RBC Capital Mkts

Date	Price Target	Rating	Analyst
6/30/2025		Buy → Hold	D. Boral Capital
6/30/2025	$20.00	Buy	H.C. Wainwright
3/7/2025	$18.00	Outperform	Leerink Partners
1/13/2025	$15.00	Buy	D. Boral Capital
8/26/2024	$13.00	Buy	Rodman & Renshaw
8/10/2023	$6.00	Outperform	RBC Capital Mkts

Date

Price Target

Rating

Analyst

6/30/2025

Buy → Hold

D. Boral Capital

6/30/2025

$20.00

Buy

H.C. Wainwright

3/7/2025

$18.00

Outperform

Leerink Partners

1/13/2025

$15.00

Buy

D. Boral Capital

8/26/2024

$13.00

Buy

Rodman & Renshaw

8/10/2023

$6.00

Outperform

RBC Capital Mkts

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

Crush Q3 2025 with the Best AI Superconnector

Q&A

When will CorMedix report its financial results?

What time is the corporate update conference call scheduled for?

What is the name of CorMedix's lead product and when was it approved by the FDA?

When did CorMedix launch DefenCath in different patient settings?

Where can investors find more information about CorMedix?

Recent Analyst Ratings for $CRMD

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

Crush Q3 2025 with the Best AI Superconnector

Q&A

When will CorMedix report its financial results?

What time is the corporate update conference call scheduled for?

What is the name of CorMedix's lead product and when was it approved by the FDA?

When did CorMedix launch DefenCath in different patient settings?

Where can investors find more information about CorMedix?

Recent Analyst Ratings for $CRMD

$CRMD Press Releases

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

$CRMD Analyst Ratings

Cormedix downgraded by D. Boral Capital

H.C. Wainwright initiated coverage on Cormedix with a new price target

Leerink Partners initiated coverage on Cormedix with a new price target

$CRMD SEC Filings

CorMedix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

SEC Form 10-Q filed by CorMedix Inc.

CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events

$CRMD FDA approvals

November 17, 2023 - FDA Roundup: November 17, 2023

FDA Approval for DEFENCATH issued to CORMEDIX INC

$CRMD Insider Purchases

EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

$CRMD Insider Trading

Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

Chief Executive Officer Todisco Joseph exercised 59,170 shares at a strike of $3.38, increasing direct ownership by 13% to 530,721 units (SEC Form 4)

Chief Executive Officer Todisco Joseph was granted 187,500 shares and covered exercise/tax liability with 23,977 shares, increasing direct ownership by 53% to 471,551 units (SEC Form 4)

$CRMD Leadership Updates

CorMedix Inc. Announces Appointment of Chief Legal Officer

CorMedix Inc. Announces Partnership With The Leapfrog Group

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

$CRMD Financials

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

$CRMD Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

SEC Form SC 13G filed by CorMedix Inc.

Recent Analyst Ratings for
$CRMD

Recent Analyst Ratings for
$CRMD

$CRMD
Press Releases

$CRMD
Analyst Ratings

$CRMD
SEC Filings

$CRMD
FDA approvals

$CRMD
Insider Purchases

$CRMD
Insider Trading

$CRMD
Leadership Updates

$CRMD
Financials

$CRMD
Large Ownership Changes